Marksans Pharma Reports Robust Q2 FY27 Consolidated Results Alongside Key European Acquisitions
Marksans Pharma Ltd · Outcome · 04 Nov 2026, 7:04 pm
Marksans Pharma Reports Robust Q2 FY27 Consolidated Results Alongside Key European Acquisitions Marksans Pharma posted consolidated revenue from operations of ₹9,401.69 mn for the quarter ended 30th Sep'26, up 30.5% YoY from ₹7,204.09 mn and 11.8% QoQ. Consolidated net profit attributable to owners reached ₹1,413.12 mn versus ₹982.50 mn in Q2 FY26 (up 43.8% YoY). For H1 FY27, revenue rose 32.8% YoY to ₹17,809.65 mn with PAT of ₹2,984.79 mn. The company completed 100% acquisitions of Dutch distributor QliniQ B.V. for EUR 7.50 mn and German-based ABCnow GmbH for EUR 1.10 mn.
Original exchange filing (PDF)
More announcements from Marksans Pharma Ltd
- Transcript of Investors/Analyst meet on Q2 FY27 Financial Results · 13 Nov 2026
- Audio Recording of investor(s)/analyst(s) meet Conference Call on Q2 FY 27 Financial Results · 05 Nov 2026
- Allotment of Equity Shares under Marksans Employees Stock Option Scheme 2024 · 04 Nov 2026
- Press Release for Financial Results Q2FY27 · 04 Nov 2026
- Investor Presentation Q2FY27 · 04 Nov 2026
- Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended 30 September 2026 · 04 Nov 2026
- Please find attached outcome of the Board meeting held on 04 November 2026 · 04 Nov 2026
- Intimation of schedule for Q2FY27 Earnings Conference Call · 05 Nov 2026
